| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Susanne Krüger Kjaer | Q38297251 |
| Paolo Bonanni | Q47135409 | ||
| Catherine Cohet | Q56436088 | ||
| P2093 | author name string | Richard M Haupt | |
| Keith Reisinger | |||
| Paul-Henri Lambert | |||
| Nina B Latham | |||
| P2860 | cites work | Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions | Q28301685 |
| Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18 | Q33910699 | ||
| Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases | Q34627305 | ||
| Vaccine-induced pathogen strain replacement: what are the mechanisms? | Q36801980 | ||
| Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination | Q37376697 | ||
| Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada | Q39967888 | ||
| Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. | Q40450678 | ||
| Attitudes to HPV vaccination among parents of children aged 12-15 years-a population-based survey in Sweden | Q43912644 | ||
| Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine | Q44326891 | ||
| A five‐year evaluation of reports of overdose with indinavir sulfate | Q44598996 | ||
| Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions | Q45399390 | ||
| Epidemiology and costs associated with genital warts in Canada | Q46599926 | ||
| Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. | Q46870430 | ||
| The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. | Q51727827 | ||
| HPV infection in Europe | Q58280584 | ||
| HPV genotype prevalence in cytologically abnormal cervical samples from women living in south Italy | Q62660928 | ||
| Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial | Q83988269 | ||
| P433 | issue | 30 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4719-4730 | |
| P577 | publication date | 2010-05-06 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD | |
| P478 | volume | 28 |
| Q38006991 | A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. |
| Q36259403 | A review of clinical trials of human papillomavirus prophylactic vaccines |
| Q35927665 | Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice |
| Q35100779 | An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines |
| Q37802640 | Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. |
| Q34210255 | Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data |
| Q35128768 | Global challenges of implementing human papillomavirus vaccines |
| Q85055469 | HPV related surveillance activities in Australia |
| Q84790071 | HPV vaccination and cervical cancer |
| Q64127955 | HPV vaccine effect: is the glass half full or half empty? |
| Q38064062 | Human papillomavirus vaccine introduction--the first five years |
| Q34611400 | Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard |
| Q50091385 | Monitoring the impact of HPV vaccine in males-Considerations and challenges |
| Q37908267 | Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009. |
| Q35258843 | Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer |
| Q35887140 | Parents' decision-making about the human papillomavirus vaccine for their daughters: I. Quantitative results |
| Q37996715 | Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study |
| Q37912228 | Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact |
| Q33166996 | Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States |
| Q36270681 | Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males |
| Q37818140 | Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women |
| Q38229304 | Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts |
| Q27013956 | Safety assessment of adjuvanted vaccines: Methodological considerations |
| Q30401949 | Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance |
| Q33162724 | Safety of human papillomavirus vaccines: a review. |
| Q47554428 | Strengthening the case for gender-neutral and the nonavalent HPV vaccine |
| Q34812959 | Towards the eradication of HPV infection through universal specific vaccination |
| Q26783879 | Vaccine Adjuvants: from 1920 to 2015 and Beyond |
Search more.